NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 301)
Posted On: 01/10/2020 3:28:34 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Posts Strategic Company Update
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, on Thursday provided a strategic update from the company’s CEO Chris Bunka. Among other highlights, the update includes a brief recap of achievements from 2019 and an outlook for the new year. “One objective for the company during 2020 is to dramatically alter our capital markets strategy. During the last six months Lexaria has met with a number of Wall Street investment banking firms as we devise our long-term capital markets strategy. Lexaria expects to pursue a strategy during 2020 to qualify for listing on a nationally-recognized US exchange, allowing a dramatically larger audience of investors to consider Lexaria’s attributes and opening a path to increased quantity and quality of strategic opportunities,” Lexaria Bioscience CEO Chris Bunka stated in the update.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, on Thursday provided a strategic update from the company’s CEO Chris Bunka. Among other highlights, the update includes a brief recap of achievements from 2019 and an outlook for the new year. “One objective for the company during 2020 is to dramatically alter our capital markets strategy. During the last six months Lexaria has met with a number of Wall Street investment banking firms as we devise our long-term capital markets strategy. Lexaria expects to pursue a strategy during 2020 to qualify for listing on a nationally-recognized US exchange, allowing a dramatically larger audience of investors to consider Lexaria’s attributes and opening a path to increased quantity and quality of strategic opportunities,” Lexaria Bioscience CEO Chris Bunka stated in the update.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)